Abstract:BACKGROUND: Reprogramming resident glial cells to convert them into neurons in vivo represents a potential therapeutic strategy that could replenish lost neurons, repair damaged neural circuits, and restore function. AAV (adeno-associated virus)-based expression systems are powerful tools for in vivo gene delivery in glia-to-neuron reprogramming, however, recent studies show that AAV-based gene delivery of Neurod1 into the mouse brain can cause severe leaky expression into endogenous neurons leading to misinterpretation of glia-to-neuron conversion.METHODS: AAV-based delivery systems were modified for improved in vivo delivery of Neurod1, Math5, Ascl1, and Neurog2 in the adult mouse retina and brain. To examine whether bona fide glia-to-neuron conversion occurs, stringent fate mapping experiments were performed to trace the lineage of glial cells.FINDINGS: The neuronal leakage is prevalent after AAV-GFAP-mediated delivery of Neurod1, Math5, Ascl1, and Neurog2. The transgene-dependent leakage cannot be corrected after lowering the AAV doses, using alterative AAV serotypes or injection routes. Importantly, we report the development of two new AAV-based tools that can significantly reduce neuronal leakage. Using the new AAV-based tools, we provide evidence that Neurod1 gene transfer fails to convert lineage traced glial cells into neurons.INTERPRETATION: Stringent fate mapping techniques independently of an AAV-based expression system are the golden standard for tracing the fate of glia cells during neuronal reprogramming. The newly developed AAV-based systems are invaluable tools for glia-to-neuron reprogramming in vivo.FUNDING: The work in Chen lab was supported by National Institutes of Health (NIH) grants R01 EY024986 and R01 EY028921, an unrestricted challenge grant from Research to Prevent Blindness, the New York Eye and Ear Infirmary Foundation, and The Harold W. McGraw, Jr. Family Foundation for Vision Research. The work in Zhang lab was supported by NIH (R01 NS127375 and R01 NS117065) and The Decherd Foundation.

Repressing PTBP1 Fails to Convert Reactive Astrocytes to Dopaminergic Neurons in a 6-Hydroxydopamine Mouse Model of Parkinson’s Disease

Repressing PTBP1 is Incapable to Convert Reactive Astrocytes to Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease

Downregulating PTBP1 Fails to Convert Astrocytes into Hippocampal Neurons and to Alleviate Symptoms in Alzheimer's Mouse Models.

Ptbp1 knockdown failed to induce astrocytes to neurons in vivo

Reducing Polypyrimidine Tract‑binding Protein 1 Fails to Promote Neuronal Transdifferentiation on HT22 and Mouse Astrocyte Cells under Physiological Conditions.

Reversing a model of Parkinson's disease with in situ converted nigral neurons

Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model for Parkinson's disease

Genetic loss of function of Ptbp1 does not induce glia-to-neuron conversion in retina

Myt1l induced direct reprogramming of pericytes into cholinergic neurons.

Reprogrammed Astrocytes As a Potential Therapy for Neurodegenerative Disorders.

Selective Generation of Dopaminergic Precursors from Human Fibroblasts by Direct Lineage Conversion

Differentiation of Adult Human Retinal Pigment Epithelial Cells into Dopaminergic-Like Cells in Vitro and in the Recipient Monkey Brain

Epigenetic Dynamics in Reprogramming to Dopaminergic Neurons for Parkinson's Disease

Induced Expression of kir6.2 in A1 Astrocytes Propagates Inflammatory Neurodegeneration via Drp1-dependent Mitochondrial Fission

Generation of naivetropic induced pluripotent stem cells from Parkinson's disease patients for high efficiency genetic manipulation

Efficient Generation of Dopaminergic Neurons from Mouse Ventral Midbrain Astrocytes

In situ Chemical Reprogramming of Astrocytes into Neurons: A New Hope for the Treatment of Central Neurodegenerative Diseases?

Selective Generation of Dopaminergic Precursors from Mouse Fibroblasts by Direct Lineage Conversion

New AAV tools fail to detect Neurod1-mediated neuronal conversion of Müller glia and astrocytes in vivo

Induction of Parkinsonian-like changes via targeted down-regulation of astrocytic glutamate transporter GLT-1 in the striatum

Cell type- and region-specific translatomes in an MPTP mouse model of Parkinson's disease